Aerosol formulations and aerosol delivery of scopolamine
US7410635B2 · kind B2 · utility
12Cited by
22References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 6, 2004 |
| Grant date | Aug 12, 2008 |
| Priority date | — |
| Expiry date | Jan 5, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M15/025
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A liquid aerosol formulation comprising at least one thermally stable active ingredient selected from the group consisting of butalbital, lorazepam, ipratropium, baclofen, morphine, scopolamine, pharmaceutically acceptable salts and esters thereof and derivatives thereof. The liquid formulation can include an organic solvent such as propylene glycol and one or more optional excipients. The active ingredient can be present in an amount of 0.01 to 5 weight percent and the formulation can be heated to provide a vapor which forms an aerosol having a mass median aerodynamic diameter of less than 3 μm.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.